Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

Status Recruiting

Clinical Trial Summary

This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.

Clinical Trial Description

Participants with active RA flair will be assigned to take on one of two Acthar doses, either 40 units per week or 80 units twice a week. Both arms will be taking the drug for 4 weeks. Each participant will be coming back for visits at 2 weeks, 1 month and 3 months after the initial baseline visit. During these visits the following information will be collected: MSUS of joints, DAS28, Clinical Disease Activity Index (CDAI), Routine Assessment of Patient Index Data 3 (RAPID3) and Health Assessment Questionnaire-Disability Index (HAQ-DI). Participants will also be asked to fill out a questionnaire about their health status. Efficacy of Acthar to decrease evidence of MSUS synovitis and disease activity measures will be analyzed using the above mentioned instruments, as well as Acthar's ability to prevent the necessity to change patients' RA treatment regimen. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02541955
Study type	Interventional
Source	University of California, Los Angeles
Contact	Veena K Rangantah, M.D., M.S.
Phone	310-825-3061
Email	vranganath@mednet.ucla.edu
Status	Recruiting
Phase	Phase 4
Start date	July 20, 2017
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05047341` - A Study of Human Substance Balance and Biotransformation of [14C]SHR0302	Phase 1
Withdrawn	`NCT02786563` - Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
Completed	`NCT03257852` - A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate	Phase 2
Completed	`NCT03660059` - A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)	Phase 3
Recruiting	`NCT03971253` - Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Not yet recruiting	`NCT05486715` - Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients
Completed	`NCT03682705` - A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis	Phase 2
Active, not recruiting	`NCT04574492` - A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
Active, not recruiting	`NCT02805010` - Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously	Phase 1
Completed	`NCT01871961` - Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient	Phase 1
Active, not recruiting	`NCT04497597` - A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Terminated	`NCT02775656` - UCB Cimzia Pregnancy Follow-up Study
Completed	`NCT01173120` - Methotrexate - Inadequate Response Device Sub-Study	Phase 3
Completed	`NCT03223012` - Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
Completed	`NCT03086343` - A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs	Phase 3
Terminated	`NCT01569152` - Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)	Phase 2
Completed	`NCT02105129` - A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523	Phase 1
Completed	`NCT01618955` - Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device	Phase 2
Completed	`NCT01577563` - Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).	N/A
Completed	`NCT01618968` - Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device	Phase 2